Coagulation disorders in patients with abnormal serum cortisol level

Yifan Liu1, Tianrui Yang1, Yong Yao3, Ming Feng1, Mengyao Wan1, Shanshan Feng1, Xiaohai Liu1, Kan Deng1, Bing Xing1, Lin Lu2, Huijuan Zhu2, Renzhi Wang1, Xinjie Bao1

1Department of Neurosurgery, Pituitary Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
2Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.

To the Editor: Cortisol is closely related to hemostasis.1] In patients with hyperadrenalism, that is, Cushing syndrome (CS), a reduction in the activated partial thromboplastin time (APTT), an increased level of coagulation factors, and an increased risk of thrombosis have been repeatedly reported.1]-2) However, no studies reported the hemostatic status of patients with hypoadrenalism which is commonly seen in patients with pituitary diseases.

We undertook a retrospective study designed to evaluate the hemostatic status in patients with hypoadrenalism or hyperadrenalism. The study protocol was approved by the Ethics Review Board of Peking Union Medical College Hospital. All patients provided written informed consent to participate.

Clinical records of patients with pituitary adenomas were reviewed if they were hospitalized in the Department of Neurosurgery of our hospital from 2012 to 2018. In brief, the diagnosis of Cushing disease (CD) was based on the clinical symptoms and signs, magnetic resonance imaging, and hormone assays including low-dose and high-dose dexamethasone suppression test, inferior petrosal sinus sampling, and positive pathologically immunohistological staining for adrenocorticotropic hormone (ACTH). Patients with CD were considered as the hyperadrenalism group (hyperA). Non-functional pituitary adenoma (NF) was diagnosed based on normal endocrinological results and negative pathologically immunohistological staining. Patients with pituitary adenoma and pre-operative morning serum cortisol level (MSCL, at 08:00 AM) < 138 nmol/L (5 µg/dL) were considered as the hypoadrenalism group (hypoA). Patients with NF and normal endocrinological results were considered as NF control group (NFC).

Healthy people who underwent annual physical examination in our hospital in the same period were considered as the healthy control (HC). Participants were excluded if they used any exogenous glucocorticoid (eg, hydrocortisone and prednisolone) 6 months before hospital admission or if they had no results of coagulation tests.

After hospital admission, blood was drawn at 08:00 AM for tests. Coagulation tests were evaluated using the Sysmex® CS-5100 Hemostasis system (Siemens Healthcare Diagnostics, Erlangen, Germany). The reference ranges of prothrombin time (PT), prothrombin activity, international normalized ratio (INR), APTT, thrombin time, and fibrinogen level were 10.4 to 12.6 s, 74.0% to 120.0%, 0.84 to 1.18, 22.7 to 31.8 s, 14.0 to 21.0 s, and 1.80 to 3.50 g/L, respectively, in our hemostasis laboratory. The serum cortisol, ACTH, insulin-like growth factor (IGF)-1 level, and thyroid function were evaluated using the direct chemiluminescent immunoassay method with the ADVIA Centaur® XP Immunoassay system or the IMMULITE® 2000 Immunoassay system (Siemens Healthcare Diagnostics, Tarrytown, NY, USA). The standard deviation score of IGF-1 was calculated as follow $\frac{[(X/M)^2-1]}{(L \times S)}$, where $X$ was an individual IGF-1 measurement, and $L$, $M$, and $S$ were the age-specific parameters.

In total, 73 patients in hypoA group, 136 patients with CD (hyperA group), 124 patients in the NFC group, and 79 HCs were used for analysis. No participants had a history of coagulation disorders.

As shown in Supplementary Table 1, http://links.lww.com/CM9/A604, the mean age of patients with hypoA was 45.0 years, and 30.1% were females. The systolic pressure of hypoA was similar to that of HC, significantly lower than that of NFC ($P = 0.002$), while no difference was found in diastolic pressure between hypoA and NFC or HC. As for liver function tests, there was a difference between patients with hypoA and HC in alanine transaminase (ALT), aspartate transaminase, albumin, and alkaline phospha-
Our study analyzed the hemostatic disorders in patients with hypoadrenalism for the first time, indicating that both APTT and PT were significantly prolonged in hypoA and were significantly shortened in patients with CD.

Previous studies \( {\text{(in vitro or in vivo)}} \) exploring the hemostatic abnormalities in hypoA are lacking.\(^{[1]} \) However, there were some studies on hypercortisolism, such as CS, which might provide clues about the effect of cortisol on coagulation. Most of those studies have indicated that the levels of components in the coagulation cascade are increased significantly in CS, especially factors VIII and IX.\(^{[2-4]} \) A reduction of APTT in CS has been described repeatedly,\(^{[1-4]} \) which might be the outcome of an increased level of factors VIII and IX. Besides, Brotman et al.\(^{[5]} \) showed that healthy volunteers who took dexamethasone (per os) for 5 days had significantly higher levels of factors VII, VIII, XI, and fibrinogen. Our study found a significantly decreased APTT and PT in patients with CD, comparing with NFC or HC, which was consistent with previous studies. These results could be extrapolated to suggest that patients with hypoA would have lower levels of factors VIII and IX, leading to an increase in APTT.

This was a rare study to assess coagulation abnormalities in patients with hypoadrenalism, which may have several potential clinical implications. For example, APTT might be used to monitor the dosage of glucocorticoid replacement therapy (GRT) in patients with hypoadrenalism. Although GRT is recommended and used widely for the treatment of hypoadrenalism, an accurate monitor for the glucocorticoid dose is lacking. In GRT, short-acting glucocorticoids such as hydrocortisone and prednisolone are the main choices; thus, the MSCL is not an accurate way to monitor the glucocorticoid dose. Nowadays, the glucocorticoid dose is adjusted to ascertain the optimal glucocorticoid dose based primarily on the experience of the treating physician. Our results indicated that APTT might be useful to monitor the dose of glucocorticoids in GRT. An increased APTT indicates an insufficient dose of the glucocorticoid, whereas a decreased APTT indicates overuse of the glucocorticoid. However, further studies are needed to confirm the clinical value of APTT in monitoring the glucocorticoid dose.

In conclusion, coagulation disorders are found in patients with hypoA or hyperA mainly in the intrinsic pathways. APTT is significantly prolonged in hypoA and shortened in hyperA, which might have potential clinical implications.
Funding

This work was supported by grants from the National Key R&D Program of China (No. 2018YFA0108600), the Beijing Natural Science Foundation (No. 7182134), the CAMS Initiative for Innovative Medicine (CAMS-I2M) (No. 2016-I2M-1-017), the CAMS Young Talents Award Project (No. 2018RC320003), and the Beijing Nova Program (No. Z181100006218003).

Conflicts of interest

None.

References

1. Isidori AM, Minnetti M, Sbardella E, Graziadio C, Grossman AB. Mechanisms in endocrinology: the spectrum of haemostatic abnormalities in glucocorticoid excess and defect. Eur J Endocrinol 2015;173:R101–R113. doi: 10.1530/EJE-15-0308.

2. Manetti L, Bogazzi F, Giovannetti C, Raffaelli V, Genovesi M, Pellegrini G, et al. Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing’s syndrome: results from a prospective study before and after surgery. Eur J Endocrinol 2010;163:783–791. doi: 10.1530/EJE-10-0583.

3. van der Pas R, de Bruin C, Leebeek FWG, de Maat MPM, Rijken DC, Pereira AM, et al. The hypercoagulable state in Cushing’s disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy. J Clin Endocrinol Metab 2012;97:1303–1310. doi: 10.1210/jc.2011-2753.

4. Coelho MCA, Vieira Neto L, Kasuki L, Wildemberg LE, dos Santos CV, Castro G, et al. Rotation thromboelastometry and the hypercoagulable state in Cushing’s syndrome. Clin Endocrinol (Oxf) 2014;81:655–664. doi: 10.1111/cen.12491.

5. Brotman DJ, Girod JP, Posch A, Jani JT, Patel JV, Gupta M, et al. Effects of short-term glucocorticoids on hematostatic factors in healthy volunteers. Thromb Res 2006;118:247–252. doi: 10.1016/j.thromres.2005.06.006.

How to cite this article: Liu Y, Yang T, Yao Y, Feng M, Wan M, Feng S, Liu X, Deng K, Xing B, Lu L, Zhu H, Wang R, Bao X. Coagulation disorders in patients with abnormal serum cortisol level. Chin Med J 2022;135:240–242. doi: 10.1097/CMJ.0000000000001567